Semax has been investigated for effects on neurotrophins, proteins involved in nerve-cell function. Rat studies measured changes in BDNF-related signalling and learning behaviour. These experiments provide a reason to study nervous-system effects, but they do not establish sharper focus, better memory or protection against neurological disease in healthy people.

A study in people recovering from ischemic stroke examined Semax alongside rehabilitation and reported changes in BDNF and functional scores. Stroke recovery is a specific clinical setting, and the study’s design limits how strongly the effect can be attributed to Semax. These findings should not be repackaged as a general cognitive-enhancement benefit.

Selank has a separate research history involving anxiety symptoms. Its results do not validate Semax, and findings for either peptide cannot demonstrate that a combined product improves both mood and focus. Readers should look for the exact compound, study population, comparison group and measured outcome before interpreting a benefit claim.

Selank has small human studies on anxiety symptoms, while Semax has laboratory neurotrophin research and limited studies in stroke rehabilitation. These are separate evidence bases. They explain interest in a combination, but do not establish that the listed Selank plus Semax blend improves both mood and focus, or provides a broader cognitive benefit.

A result for either ingredient alone cannot determine the effect of a mixture. The blend could differ in absorption, stability, tolerability or clinical response. Demonstrating an advantage requires direct comparison of the exact formulation with its components and a control. DSIP’s separate, mixed sleep findings do not add evidence that this blend improves sleep.